Addressing Unmet Needs in Lung Cancer With Rational Immunotherapy-Based Approaches: Evidence and Practicalities
Nov. 10, 2017
Registration and Lunch: 12:15 - 12:45 p.m.
Symposium: 12:45 - 1:45 p.m.
Gaylord National Hotel
It is clear that immunotherapy has already become a key pillar in the treatment of advanced NSCLC, but new data have emerged recently that are showing potential for further changing clinical practice, and there are also a number of critical questions that still need to be answered by ongoing research. In the oncology community, there is a lot of interest in strategies that may expand on the benefits currently seen with immunotherapies in lung cancer. To that end, a wide range of single-agent and combinatorial immune-based treatment approaches are being explored in various settings and populations to assess their role and potential for further improving outcomes. Finding better biomarkers for predicting benefit from immunotherapies is another area where intense research efforts are underway. The most important aspect to consider is how to interpret the vast amount of accumulating evidence and translate it into everyday patient care in a rational and meaningful manner.
If you could benefit from a concise and focused overview of the present and future of immunotherapy in lung cancer, this Live Master Class and Practicum is for you! Drs. Naiyer Rizvi and Melissa Johnson will hold an interactive discussion highlighting the current state of the science as well as new promising directions. They will also debate what this means for clinicians, researchers, and patients, and provide practical guidance for effectively navigating the rapidly changing and complex lung cancer treatment landscape in the era of immuno-oncology.
For more information and to register, please visit: www.peerviewpress.com/ITClung17
Upon completion of this activity, participants should be better able to:
- Analyze the efficacy and safety of immunotherapies and immune-based combinations in different types and settings of lung cancer based on the evidence from the latest clinical trials
- Discuss the indications for and roles of immunotherapies and combinations in the treatment of different types and settings of lung cancer
- Integrate immunotherapies either as monotherapies or as part of rational combinations into treatment plans for appropriate patients with lung cancer according to the latest evidence and recommendations
- Refer patients with lung cancer to clinical trials assessing novel strategies with immunotherapies and combinations to further advance the field, address unmet needs, and improve patient outcomes
This activity has been designed to meet the educational needs of oncologists and other healthcare professionals as well as researchers involved in advancing the care of patients with lung cancer through optimal use of cancer immunotherapies.
This CME activity is jointly provided by Medical Learning Institute, Inc., and PVI, PeerView Institute for Medical Education.
This activity is supported by an independent educational grant from AstraZeneca.